Study details
Enrolling now
AMSC Trial for Anastomotic Stenosis
Houssam Farres, M.D.
NCT IDNCT04392206ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
15
Study length
about 7.1 years
Ages
18–85
Locations
1 site in FL
About this study
Researchers are testing the safety of using Adipose Derived Mesenchymal Stem Cells (AMSC) to improve access maturation and primary anastomotic patency in patients with Chronic Kidney Disease undergoing arteriovenous fistulas or arterial bypasses. The trial will last approximately 2602 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Adipose Derived Mesenchymal Stem Cells
PhasePhase 1
Primary goalNumber of participants with treatment-related adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of participants with treatment-related adverse events
Body systems
Renal